|
The goal of the Drug Development Program web site
is to facilitate communication about the Drug Development Program, the
Phase II Consortium and current and upcoming clinical trials.
DRUG DEVELOPMENT PROGRAM
Dr. Malcolm Moore, the director of the program, states “We hope that by making
physicians more aware of our current clinical trials, we will be able
to offer patients a greater opportunity to be involved in studies with
novel anti-cancer agents and make further advances in the treatment and
control of cancer.”
The Drug Development Program has rapidly increased its staff over the
last few years due to the growth of the program and the number of high-quality
clinical trials. The main staff list is as follows:
Staff
|
|
| Dr. Malcolm Moore |
Director |
| Dr. Amit Oza |
Co-Director |
| Dr. Lillian Siu |
Co-Director |
| Dr. Eric Chen |
Co-Director |
| |
|
Administrative
|
|
| Maryke Abbott |
Administrative Coordinator |
| Robin Cheiken |
Program Manager – Phase I |
Katrina MacAlpine |
Program Manager – Phase II |
| Sheila Webster |
Nurse Manager Clinical Trials – DMOH |
| |
|
Clinical
|
|
| Dr. Carol Townsley |
Clinical Associate |
| |
|
Pharmacy
|
|
| Jane Nagai |
Pharmacist |
| |
|
We also have a dedicated staff of clinical research coordinators, fellows, assistant managers and students.
DRUG DEVELOPMENT PROGRAM GOALS
- 1. To rapidly conduct clinical trials designed to assess the antitumour
activity of novel agents, either alone or in combination.
- To implement appropriate translational research studies that complement
phase II studies to allow elucidation of:
- Mechanism of action of anti-cancer drugs
- Mechanism of drug resistance
- Molecular factors predicting for response and resistance
- Tumour microvasculature and angiogenesis
- To conduct timely and high quality clinical and translational studies.
- To regard patient safety to be paramount during the design and implementation
of every study.
|
